Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | AHCY | P23526 | 5/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | GNMT | Q14749 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038453 | 0.84 | AHCY (0.44) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL4394104 | 0.83 | AHCY (0.43) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL5481897 | 0.78 | AHCY (0.57) | AHCYHIF1ATMEM97SIGMAR1GNMT | |
| SCHEMBL24673102 | 0.77 | PRMT5 (0.58) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL24673985 | 0.77 | PRMT5 (0.58) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL22707421 | 0.76 | PRMT5 (0.54) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL3660264 | 0.72 | NT5E (0.40) | AHCYHIF1AADORA3ADORA1ADORA2A | |
| SCHEMBL8652181 | 0.71 | PRMT5 (0.50) | PRMT5WDR77AHCYHIF1ATMEM97 | |
| SCHEMBL5040710 | 0.70 | ADORA3 (0.45) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL22799204 | 0.70 | AHCY (0.55) | AHCYHIF1ATMEM97SIGMAR1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771344-B1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITÉ PIERRE ET MARIE CURIE PARIS 6 (FR) | 2016-04-13 | — | — | EP | claimed |
| US-9181294-B2 | Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-11-10 | — | — | US | claimed |
| US-20140323425-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2014-10-30 | — | — | US | claimed |
| EP-2771344-A1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | Université Pierre et Marie Curie (Paris 6) (FR) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060980-A1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2013-05-02 | — | — | WO | claimed |
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-01-19 | — | — | US | disclosed |
| EP-4025583-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | Centre national de la recherche scientifique (FR) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021043992-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-03-11 | — | — | WO | disclosed |
| EP-3789393-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | Centre National de la Recherche Scientifique (FR) | 2021-03-10 | — | — | EP | disclosed |
| EP-2771344-B1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITÉ PIERRE ET MARIE CURIE PARIS 6 (FR) | 2016-04-13 | — | — | EP | disclosed |
| US-9181294-B2 | Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-11-10 | — | — | US | disclosed |
| US-20140323425-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2014-10-30 | — | — | US | disclosed |
| EP-2771344-A1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | Université Pierre et Marie Curie (Paris 6) (FR) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013060980-A1 | NUCLEOSIDE ANALOGUES FOR TREATING A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2010056795-A1 | NOVEL SYNTHETIC DINUCLEOSIDE POLYPHOSPHATE ANALOGS AND THEIR USE AS NEW THERAPEUTIC AND/OR DIAGNOSTIC MODALITIES | ZATA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7319093-B2 | Antidiabetic 2-substituted-5′-O-(1-Boranotriphosphate) adenosine derivatives | BAR-ILAN UNIVERSITY (IL) | 2008-01-15 | — | — | US | disclosed |
| EP-1446132-A4 | ANTIDIABETIC 2-SUBSTITUTED-5'-O- (1-BORANOTRIPHOSPHATE) ADENOSINE DERIVATIVES | UNIV BAR ILAN (IL) | 2006-02-15 | — | — | EP | disclosed |
| US-20050065108-A1 | Antidiabetic agents; antilipemic agents | UNIVERSITY OF MONTPELLIER I (FR) | 2005-03-24 | — | — | US | disclosed |
| EP-1446132-A2 | ANTIDIABETIC 2-SUBSTITUTED-5'-O- (1-BORANOTRIPHOSPHATE) ADENOSINE DERIVATIVES | BAR-ILAN UNIVERSITY (IL) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003034978-A2 | ANTIDIABETIC 2-SUBSTITUTED-5'-O- (1-BORANOTRIPHOSPHATE) ADENOSINE DERIVATIVES | BAR-ILAN UNIVERSITY (IL) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065108-A1 | Antidiabetic agents; antilipemic agents | NPR3, NR4A3, NOX3 | PRMT5 1583/4885WDR77 2943/4885AHCY 1789/4885 |
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | STING1, CGAS, MAVS | PRMT5 960/4885WDR77 1731/4885AHCY 3830/4885 |
| US-20140323425-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT | SAMHD1, NUDT1, TYMP | PRMT5 1354/4885WDR77 682/4885AHCY 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.